Cancer News and Research

Latest Cancer News and Research

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Access to dermatologist improves melanoma-related health outcomes

Individuals whose melanoma is diagnosed by a dermatologist may be more likely to have early-stage cancer and to survive five years than those with melanoma diagnosed by a non-dermatologist, according to a report in the April issue of Archives of Dermatology.

17 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007

Cortical mapping helps brain tumor removal

In 2006, it was estimated that 18,820 new cases were diagnosed and 12,820 deaths were associated with malignant tumors of the brain and other parts of the central nervous system.

17 Apr 2007

Chromosomes tell tale of patient's risk for new, future cancer

Hodgkin's disease survivors who have greater genetic instability in their white blood cells are two-and-a-half times more likely to develop another type of cancer, researchers from The University of Texas M. D.Anderson Cancer Center report at the American Association for Cancer Research annual meeting in Los Angeles April 14-18.

17 Apr 2007

Cetuximab improves survival and slows progression of colorectal cancer

Research presented at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted, cetuximab.

17 Apr 2007

Breastfeeding reduces risk of invasive breast cancer

Breastfeeding can offset the increased risk of invasive breast cancer for women who had their first full-term pregnancy after the age of 25, a study led by researchers at the University of Southern California (USC) suggests.

17 Apr 2007

Biomira selects PX-866 as clinical development candidate

Biomira Inc. has announced that it has selected PX-866 as its next clinical development candidate.

17 Apr 2007

Factors that influence late stage cancer diagnosis

Researchers from the Keck School of Medicine of the University of Southern California (USC) found that patients who received a later stage cancer diagnosis were likely to be living in an unsafe neighborhood, using public transportation and traveling at least 45 minutes to get to a doctor's office.

16 Apr 2007

Epigenetic factors that increase breast cancer risk

Women can encounter environmental factors that increase their risk of breast cancer at various periods of their physical development, beginning before birth and extending until menopause.

16 Apr 2007

Socio-ecological and cultural factors attributed to later stage cancer diagnosis

16 Apr 2007

Snake venom toxin as a treatment for prostate cancer

This certainly sounds unusual, but Dr. Son and colleagues report on the effectiveness of the snake venom toxin (SVT) Vipera lebetina turanica in the inhibition of androgen-independent prostate cancer (AICAP) in the February 2007 issue of Molecular Cancer Therapeutics .

16 Apr 2007